Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 15:14:37.
doi: 10.1186/1471-2261-14-37.

Simvastatin down-regulates the production of interleukin-8 by neutrophil leukocytes from dyslipidemic patients

Affiliations

Simvastatin down-regulates the production of interleukin-8 by neutrophil leukocytes from dyslipidemic patients

Franca Marino et al. BMC Cardiovasc Disord. .

Abstract

Background: Neutrophil (PMN) leukocytes participate to the initial phases of atherosclerosis through the release of Interleukin 8 (CxCL8; IL-8) that contribute to amplification of inflammation. Aim of the study is to investigate the production of IL-8 by PMN leukocytes from dyslipidemic patients treated with simvastatin.

Methods: In 15 dyslipidemic subjects with moderately increased cardiovascular risk, assessed by Framingham Risk Score, blood samples were obtain to investigate PMNs IL-8 production [at baseline and after N-formyl-Met-Leu-Phe (fMLP) stimulation] before and after long-term (1-year) simvastatin treatment.

Results: The resting release of IL-8 was higher in dyslipidemic patients at baseline when compared with control subjects (p < 0.05). One year of treatment was significantly associated with reduced IL-8 production (p < 0.01). Moreover, the fMLP-induced IL-8 production in dyslipidemic untreated patients was higher than that of controls (p < 0.05) and was reduced after simvastatin treatment (p < 0.01). IL-8 release after 1 year of treatment was reduced to levels which were lower than those observed in control subjects both for resting and stimulated cytokine production (p < 0.01).

Conclusions: Prolonged treatment with simvastatin is associated with a reduction of IL-8 production, suggesting the possibility of statin to modulate the pro-inflammatory response in PMNs of patients with moderately increased cardiovascular risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
IL-8 production in resting (left panel) and fMLP-induced (right panel) PMNs from dyslipidemic subjects before (baseline) and during statin treatment. Horizontal lines represent the median values, boxes represent the 25th-75th percentiles, and vertical bars the minimum and maximum values. For comparison, data obtained in healthy controls are also shown: median values (solid lines) with 25th-75th percentiles (dotted lines). * = P < 0.05 and ** = P < 0.01 vs control subjects. # = P < 0.01 vs baseline.

References

    1. Galkina E, Ley K. Immune and Inflammatory Mechanisms of Atherosclerosis. Annu Rev Immunol. 2009;27:165–197. doi: 10.1146/annurev.immunol.021908.132620. - DOI - PMC - PubMed
    1. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–2138. doi: 10.1016/j.jacc.2009.09.009. - DOI - PMC - PubMed
    1. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–581. doi: 10.1152/physrev.00024.2005. - DOI - PubMed
    1. Baetta R, Corsini A. Review: Role of polymorphonuclear neutrophils in atherosclerosis: Current state and future perspectives. Atherosclerosis. 2010;210(1):1–13. doi: 10.1016/j.atherosclerosis.2009.10.028. - DOI - PubMed
    1. Yasunari K, Watanabe T, Nakamura M. Reactive oxygen species formation by polymorphonuclear cells and mononuclear cells as a risk factor of cardiovascular diseases. Curr Pharm Biotechnol. 2006;7(2):73–80. doi: 10.2174/138920106776597612. - DOI - PubMed

MeSH terms

LinkOut - more resources